BOSTON, Sept 15 (Reuters) - Cephalon Inc (CEPH.O: Quote , Profile , Research , Stock Buzz ) said on Monday that U.S. regulators will not allow it to market its painkiller Fentora for anyone other than cancer patients until the company implements ...
- Recent posts
- UPDATE 1-Cephalon says expanded Fentora label not approved - Reuters
- Expert on end-of-life care to speak at SIUC next week - Southern Illinoisan
- Cephalon Receives Complete Response Letter Regarding Request for ... - Earthtimes
- Harris Methodist Northwest Hospital Offers Pain Management Services
- Analysts not concerned about Apple's stock option irregularities - Mac Central
- Smoking may Sabotage Chronic Pain Management
- Pediatric Pain Management Alternatives for Nurses and Students
- Why do Pain Management doctors prescribe Xanax?
- F5 Networks Integration With Microsoft Offerings Delivers Optimum IT ... - Consumer Electronics Net
- Pot smoker sues for getting dismissed from pain management center
- VELCADE(R) (Black Triangle Drug) (bortezomib) Approved For Previously ... - Yahoo Finance
- Communication gap between health care professionals and pain patients - HULIQ.com
- Pain Flare Up Planning for More Effective Chronic Pain Management
- Physical therapy can help reduce pain - Pottstown Mercury
- Pain management involves more than injections - NWI.com
- Significant’ findings into lower back pain - This is Southampton
- Pain management, Oprah-style
- Tiffany D. Soares Inducted into Cambridge Who's Who Executive ... - 24-7PressRelease.com
- Laboring longer a growing trend for Americans - Detroit News
- Pain management involves more than injections - NWITimes.com